NorthWest Biotherapeutics Inc (NWBO)

[hankmanhub]

I understand where you are coming from. Sure there will be differences based on the organ in which the cancer finds itself and presumably there may be differences in what is required to treat them. But I suggest it is worth a shot that the similarities IN MOST solid cancers will allow them to be treated by the same PLATFORM without problem even if several may not (or may need some further modification to the same basic protocol). Say some 16 cancer types respond well to this treatment. Why delay approval for use in these 16 cancer types for many, many years?

In separate trial it may take many, many year, at huge cost, and those waiting with type X cancer, may have to wait for 10 to 20 years before we even get to trial for variety X cancer.. There would clearly need to be some sort of follow up procedures to determine which if any cancer types are not responding to this treatment and drop them from the label. But I believe that the greater good is for much more rapid approval and treatment for those cancers that respond well to the treatment (hopefully most solid cancer types)..